Francis Medical Expands Vanquish Prostate Ablation System to East Coast
Event summary
- Francis Medical completed its first commercial Vanquish procedure on the East Coast on March 25, 2026.
- The procedure was performed by Dr. Robert Given at Chesapeake Regional Surgery Center in Virginia Beach.
- Vanquish received FDA 510(k) clearance in November 2025 and is supported by positive interim data from the VAPOR 2 study.
- 91% of eligible patients in the VAPOR 2 study showed negative biopsy results at six months post-procedure.
The big picture
Francis Medical's expansion of the Vanquish System to the East Coast marks a strategic milestone in the adoption of minimally invasive prostate cancer treatments. The system's potential to preserve urinary and sexual function positions it as a competitive alternative to traditional surgery or radiation. The positive interim data from the VAPOR 2 study and high patient satisfaction rates suggest growing demand for innovative, less invasive options in urological cancer care.
What we're watching
- Regulatory Expansion
- Whether Francis Medical can secure pre-market approval (PMA) for an expanded indication for localized prostate cancer management.
- Market Adoption
- The pace at which the Vanquish System gains traction among urologists and patients across the U.S.
- Competitive Positioning
- How Francis Medical differentiates Vanquish from traditional prostate cancer treatments in terms of efficacy and quality of life preservation.
Related topics